Codis Expands UK Manufacturing with Commercial-Scale PSD-4 Spray Dryer at Haverhill Facility

• Codis will expand its UK manufacturing capabilities with the addition of a solvent-capable GEA Pharma-SD® type PSD-4 spray dryer at its Haverhill facility.

• The system will enable commercial-scale production of amorphous solid dispersions with batch sizes up to 500 kg and a total annual capacity of 30,000 kg, with operations planned for 2027.

Codis has announced plans to expand its manufacturing capabilities in the United Kingdom with the purchase of a GEA Pharma-SD® type PSD-4 solvent-capable spray dryer. The equipment will be installed at the company’s 400,000-square-foot facility in Haverhill, UK, and is expected to be operational in 2027. According to the company, the addition will make Codis the only CDMO in the UK offering this capacity.

The investment is supported by the UK government’s Life Sciences Innovative Manufacturing Fund (LSIMF), subject to final agreement of terms and conditions. The fund provides capital grants to life sciences manufacturers to support economic growth and strengthen resilience for future health emergencies.

The PSD-4 is a cGMP pharmaceutical spray dryer designed to produce commercial batches of up to 500 kg, with an annual production capacity of approximately 30,000 kg. The system is intended to support solvent-based spray drying of amorphous solid dispersions (ASDs), a technology used to improve the bioavailability of poorly soluble drug candidates.

The new unit will complement Codis’ existing spray drying capabilities, which include a PSD-2 system supporting pilot-scale and smaller commercial-scale production. Together, the platforms are designed to provide customers with a development-to-commercial manufacturing pathway for ASD-based drug products as part of CDMO and contract manufacturing services.

“This milestone marks the next phase in Codis’ evolution as a global leader in spray drying and ASD. The PSD4 significantly expands our ASD capacity and gives customers dedicated commercial-scale throughput to bring more life-changing medicines to market.”

Nicolas Fortin, Chief Executive Officer of Codis